EntreMed, Inc. (NASDAQ: ENMD)

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, develops therapeutic candidates mainly for the treatment of cancer and inflammation. The company has focused their efforts on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s expertise lies in angiogenesis, cell cycle regulation, cell signaling and inflammation. For further information, visit the Company’s web site at www.entremed.com.